Outlook Therapeutics, Inc. Contracts & Agreements

Description of Registrant's securities (Filed With SEC on December 27, 2024)

Outlook Therapeutics, Inc. Non-Employee Director Compensation Policy, as amended and restated, effective as of October 1, 2024 (Filed With SEC on December 27, 2024)

2024 Equity Incentive Plan (Filed With SEC on August 14, 2024)

Form of Stock Option Grant Notice and Stock Option Agreement under the 2024 Equity Incentive Plan (Filed With SEC on August 14, 2024)

Amendment, dated April 12, 2024, to Sales Agreement, dated May 16, 2023, by and between the Company and BTIG (Filed With SEC on April 12, 2024)

Form of Warrant (Filed With SEC on January 24, 2024)

Form of Syntone Warrant (Filed With SEC on January 24, 2024)

Form of Securities Purchase Agreement (Filed With SEC on January 24, 2024)

Form of Support Agreement (Filed With SEC on January 24, 2024)

Form of Registration Rights Agreement (Filed With SEC on January 24, 2024)

Syntone Purchase Agreement, dated January 22, 2024 (Filed With SEC on January 24, 2024)

Syntone Registration Rights Agreement, dated January 22, 2024 (Filed With SEC on January 24, 2024)

Third Amendment to Convertible Promissory Note, dated January 22, 2024 (Filed With SEC on January 24, 2024)

Description of Registrants securities (Filed With SEC on December 22, 2023)

Outlook Therapeutics, Inc. Non-Employee Director Compensation Policy as Amended and Restated, Effective October 1, 2023 (Filed With SEC on December 22, 2023)

Amendment, dated December 21, 2023, to the Convertible Promissory Note, dated December 22, 2022, by and between the Company and Streeterville Capital, LLC (Filed With SEC on December 22, 2023)

At-the-market-sales agreement between the Company and BTIG, LLC dated May 16, 2023 (Filed With SEC on May 16, 2023)

Amendment, dated February 10, 2023, to the Convertible Promissory Note, dated December 22, 2022, by and between the Company and Streeterville Capital, LLC (Filed With SEC on February 14, 2023)

Description of Registrants securities (Filed With SEC on December 29, 2022)

Outlook Therapeutics, Inc. Non-Employee Director Compensation Policy as Amended and Restated Effective October 1, 2020 (Filed With SEC on December 29, 2022)

Form of Warrant (Filed With SEC on December 23, 2022)

Form of Securities Purchase Agreement, dated as of December 23, 2022, by and between the Company and the Purchasers (Filed With SEC on December 23, 2022)

Letter Agreement, dated December 22, 2022, by and between the Company and M.S. Howells & Co (Filed With SEC on December 23, 2022)

Securities Purchase Agreement, dated as of December 22, 2022, by and between the Company and Streeterville Capital, LLC (Filed With SEC on December 22, 2022)

Form of Note (Filed With SEC on December 22, 2022)

Amended and Restated Executive Employment Agreement by and between Lawrence Kenyon and Outlook Therapeutics, Inc, dated June 2, 2022 (Filed With SEC on June 7, 2022)

Amended and Restated Investor Rights Agreement, dated April 21, 2022, by and between Outlook Therapeutics, Inc. and GMS Ventures and Investments (Filed With SEC on April 22, 2022)

Executive Employment Agreement by and between Terry Dagnon and Outlook Therapeutics, Inc, dated December 21, 2021 (Filed With SEC on December 23, 2021)

Executive Employment Agreement by and between Jeff Evanson and Outlook Therapeutics, Inc, dated December 21, 2021 (Filed With SEC on December 23, 2021)

Amended and Restated Underwriting Agreement, dated November 23, 2021, by and between the Company and H.C. Wainwright & Co., LLC (Filed With SEC on November 29, 2021)

Form of Underwriter Warrant (Filed With SEC on November 29, 2021)

Note Purchase Agreement between the Company and Streeterville Capital, LLC, dated as of November 16, 2021 (Filed With SEC on November 16, 2021)

Promissory Note dated November 16, 2021 (Filed With SEC on November 16, 2021)

Note Amendment dated November 16, 2021 (Filed With SEC on November 16, 2021)

Amendment No.1 to Consulting Agreement between the Company and Scott Three Consulting, LLC (Evanson) dated as of November 8, 2021 (Filed With SEC on November 12, 2021)

Amendment No. 1 to Consulting Agreement between the Company and The Dagnon Group LLC (Dagnon) dated as of November 8, 2021 (Filed With SEC on November 12, 2021)

Executive Employment Agreement by and between Lawrence Kenyon and Outlook Therapeutics, Inc, dated July 27, 2021 (Filed With SEC on July 30, 2021)

Executive Employment Agreement by and between C. Russell Trenary III and Outlook Therapeutics, Inc, dated July 6, 2021 (Filed With SEC on July 9, 2021)

At The Market Offering Agreement between the Company and H.C. Wainwright & Co. dated March 26, 2021 (Filed With SEC on March 26, 2021)

Securities Purchase Agreement, dated February 9, 2021, by and between the Company and GMS Ventures and Investments (Filed With SEC on February 11, 2021)

Underwriting Agreement, dated January 28, 2021, by and between the Company and H.C. Wainwright & Co., LLC (Filed With SEC on February 2, 2021)

Form of Underwriter Warrants (Filed With SEC on February 2, 2021)

Securities Purchase Agreement, dated January 28, 2021, by and between the Company and Syntone Ventures LLC (Filed With SEC on February 2, 2021)

Description of Registrants securities (Filed With SEC on December 23, 2020)

Note Purchase Agreement between the Company and Streeterville Capital, LLC, dated as of November 4, 2020 (Filed With SEC on November 6, 2020)

Promissory Note dated November 4, 2020 (Filed With SEC on November 6, 2020)

Lease Termination Agreement dated, May 6, 2020 between the Registrant and Cedar Brook Corporate Center, LP (Filed With SEC on August 14, 2020)

Form of Placement Agent Warrant (Filed With SEC on June 23, 2020)

Form of Securities Purchase Agreement, dated June 22, 2020, by and among the Company and the purchasers named therein (Filed With SEC on June 23, 2020)

Securities Purchase Agreement, dated June 22, 2020, by and between the Company and Syntone Ventures LLC (Filed With SEC on June 23, 2020)

Engagement Letter, dated June 2, 2020, by and between the Company and H.C. Wainwright & Co., LLC (Filed With SEC on June 23, 2020)

Stock Purchase Agreement, dated May 22, 2020, by and between the Company and Syntone Ventures LLC (Filed With SEC on May 28, 2020)

Form of Common Stock Purchase Warrant (Filed With SEC on February 24, 2020)

Form of GMS Stock Purchase Warrant (Filed With SEC on February 24, 2020)

Form of Placement Agent Warrant (Filed With SEC on February 24, 2020)

Form of Securities Purchase Agreement, dated February 24, 2020, by and among the Company and the purchasers named therein (Filed With SEC on February 24, 2020)

Securities Purchase Agreement by and between the Company and GMS Ventures and Investments dated February 24, 2020 (Filed With SEC on February 24, 2020)

Engagement letter dated December 10, 2019 by and between the Company and H.C. Wainwright & Co. LLC (Filed With SEC on February 24, 2020)

Fourth Amendment to Investor Rights Agreement dated September 11, 2017 by and between the Company and BioLexis Pte. Ltd. (formerly GMS Tenshi Holdings Pte. Limited), by and... (Filed With SEC on February 24, 2020)

Amendment to Warrants to Purchase Common Stock between the Company and BioLexis Pte. Ltd., dated as of January 27, 2020 (Filed With SEC on January 31, 2020)

Agreement to Amend Series A-1 Convertible Preferred between the Company and BioLexis Pte. Ltd., dated as of January 27, 2020 (Filed With SEC on January 31, 2020)

Termination Agreement and Mutual Release between the Company and MTTR LLC, dated as of January 27, 2020 (Filed With SEC on January 31, 2020)

Consulting Agreement between the Company and The Dagnon Group LLC (Dagnon), dated as of January 27 2020 (Filed With SEC on January 31, 2020)

Consulting Agreement between the Company and Scott Three Consulting, LLC (Evanson), dated as of January 27, 2020 (Filed With SEC on January 31, 2020)

Global Amendment, dated as of January 29, 2020 (Filed With SEC on January 31, 2020)

Exchange Agreement dated December 23, 2019 (Filed With SEC on December 23, 2019)

Form of Senior Secured Promissory Note (Filed With SEC on December 23, 2019)

Amendment #2 dated December 23, 2019 of Warrant Agreement between the Company and American Stock Transfer & Trust Company LLC, as warrant agent, dated as of April 12, 2019, as... (Filed With SEC on December 23, 2019)

Amendment dated March 4, 2019 of Strategic Partnership Agreement between the Registrant and MTTR LLC effective as of February 15, 2018, as amended (Filed With SEC on December 19, 2019)

Third Note Amendment dated June 28, 2019 (Filed With SEC on July 1, 2019)

Amendment #1 dated June 11, 2019 of Warrant Agreement between the Company and American Stock Transfer & Trust Company LLC, as warrant agent, dated as of April 12, 2019 (Filed With SEC on June 14, 2019)

Amendment dated June 4, 2019 of Strategic Partnership Agreement between the Company and MTTR LLC effective as of February 15, 2018, as amended (Filed With SEC on June 10, 2019)

Warrant Agreement, including form of 15-Month Warrant and form of Five-Year Warrant by and between the Registrant and American Stock Transfer & Trust Company, LLC, as Warrant... (Filed With SEC on May 15, 2019)

Separation and Release Agreement between the Registrant and Kenneth M. Bahrt, M.D., dated April 23, 2019 (Filed With SEC on April 26, 2019)

Form of Underwriting Agreement (Filed With SEC on April 9, 2019)

Form of Warrant Agreement including form of 15-Month Warrant and form of Five-Year Warrant (Filed With SEC on April 9, 2019)

Form of Underwriting Agreement (Filed With SEC on April 2, 2019)

Amendment #3 to the Warrant Agreement dated May 18, 2016, by and between Outlook Therapeutics, Inc. and American Stock Transfer & Trust Company LLC, as Warrant Agent, dated... (Filed With SEC on January 22, 2019)

Separation Agreement and Release by and between the Registrant and Stephen J. McAndrew, Ph.D., effective as of November 26, 2018 (Filed With SEC on December 18, 2018)

Strategic Partnership Agreement by and between the Registrant and MTTR, LLC, effective as of February 15, 2018, as amended by the Letter Addendum dated March 2, 2018 (Filed With SEC on December 18, 2018)

LEASE TERMINATION AGREEMENT (Filed With SEC on December 18, 2018)

Purchase Agreement by and between Oncobiologics, Inc. and BioLexis Pte. Ltd., dated November 5, 2018 (Filed With SEC on November 9, 2018)

Third Amendment to Investor Rights Agreement dated November 5, 2018 (Filed With SEC on November 9, 2018)

Second Note and Warrant Amendment and Waiver dated November 5, 2018 (Filed With SEC on November 9, 2018)

Executive Employment Agreement between Oncobiologics, Inc. and Lawrence A. Kenyon, dated October 22, 2018 (Filed With SEC on October 26, 2018)

Term Sheet, Convertible Preferred Equity Investment in Oncobiologics, Inc. by and between Oncobiologics, Inc. and GMS Tenshi Holdings Pte. Limited, dated June 20, 2018 (Filed With SEC on August 14, 2018)

Separation Agreement and Release by and between Oncobiologics, Inc. and Pankaj Mohan, Ph.D., dated July 2, 2018 (Filed With SEC on August 14, 2018)

Consulting Agreement by and between Oncobiologics, Inc. and Pankaj Mohan, Ph.D., dated July 2, 2018 (Filed With SEC on August 14, 2018)

Exchange Agreement by and between Oncobiologics, Inc. and GMS Tenshi Holdings Pte. Limited, dated July 18, 2018 (Filed With SEC on July 19, 2018)

Second Amendment to Investor Rights Agreement, dated July 18, 2018 (Filed With SEC on July 19, 2018)

Form of Warrant to Purchase Common Stock of Oncobiologics, Inc (Filed With SEC on May 15, 2018)

Purchase Agreement by and between Oncobiologics, Inc. and GMS Tenshi Holdings Pte. Limited, dated May 11, 2018 (Filed With SEC on May 15, 2018)

Amendment to Investor Rights Agreement dated May 11, 2018 (Filed With SEC on May 15, 2018)

Amendment #2 to the Warrant Agreement dated May 18, 2016 by and between Oncobiologics, Inc. and American Stock Transfer & Trust Company LLC, as Warrant Agent, dated February 9,... (Filed With SEC on February 9, 2018)

Sixth Amendment to Lease Agreement by and between Oncobiologics, Inc. and Cedar Brook 7 Corporate Center, LP, dated as of February 1, 2018 (Filed With SEC on February 7, 2018)

Form of Warrant to Purchase Common Stock of Oncobiologics, Inc (Filed With SEC on September 11, 2017)

Purchase Agreement by and between Oncobiologics, Inc. and the Investor named therein, dated September 7, 2017 (Filed With SEC on September 11, 2017)

Purchase and Exchange Agreement by and between Oncobiologics, Inc. and the Noteholders named therein, dated September 7, 2017 (Filed With SEC on September 11, 2017)

Investor Rights Agreement by and between Oncobiologics, Inc. and the Investor named therein, dated September 11, 2017 (Filed With SEC on September 11, 2017)

Form of Voting and Lock-up Agreement by and between the Investor named therein and the Director or Executive Officer of Oncobiologics, Inc. party thereto, dated September 7, 2017 (Filed With SEC on September 11, 2017)

Voting and Lock-up Agreement by and between the Investor named therein and Todd Brady, Director Oncobiologics, Inc., dated September 7, 2017 (Filed With SEC on September 11, 2017)

Form of Voting and Lock-up Agreement by and between the Investor named therein and the Stockholder of Oncobiologics, Inc. party thereto, dated September 7, 2017 (Filed With SEC on September 11, 2017)

Form of Voting and Lock-up Agreement by and between the Investor named therein and the Noteholder named therein, dated September 7, 2017 (Filed With SEC on September 11, 2017)

Lock-up Agreement by and among Oncobiologics, Inc., the Investor named therein and Pankaj Mohan, Ph.D., dated September 7, 2017 (Filed With SEC on September 11, 2017)

Note, Warrant and Registration Rights Amendment and Waiver, dated September 7, 2017 (Filed With SEC on September 11, 2017)

Oncobiologics,Inc. FirstAmendment to Note and Warrant Purchase Agreement (Filed With SEC on April 17, 2017)

PURCHASE AGREEMENT (Filed With SEC on March 9, 2017)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on March 9, 2017)

AMENDMENT TO WARRANT AGREEMENT ONCOBIOLOGICS, INC. AND AMERICAN STOCK TRANSFER & TRUST COMPANY,LLC, AS WARRANT AGENT (Filed With SEC on February 6, 2017)

REGISTRATIONRIGHTS AGREEMENT (Filed With SEC on February 3, 2017)

NOTEAND WARRANT PURCHASE AGREEMENT (Filed With SEC on December 23, 2016)

securityagreement (Filed With SEC on December 23, 2016)

INTELLECTUALPROPERTY SECURITY AGREEMENT (Filed With SEC on December 23, 2016)

WARRANT AGREEMENT ONCOBIOLOGICS, INC. AND AMERICAN STOCK TRANSFER & TRUST COMPANY,LLC, AS WARRANT AGENT (Filed With SEC on June 27, 2016)

SECURITIES PURCHASEAGREEMENT (Filed With SEC on May 19, 2016)

Oncobiologics, Inc. [________] Units 1 Each Unit Consisting of One Share of Common Stock ($0.01 par value), One Half of a Series A Warrant to purchaseOne Share of Common Stock and... (Filed With SEC on May 11, 2016)

ONCOBIOLOGICS, INC. (Filed With SEC on May 11, 2016)

WARRANT AGREEMENT ONCOBIOLOGICS, INC. AND AMERICAN STOCK TRANSFER & TRUST COMPANY,LLC, AS WARRANT AGENT (Filed With SEC on May 11, 2016)

INVESTORS’ RIGHTS AGREEMENT by and among ONCOBIOLOGICS, INC., STRIDES PHARMA INC. and CERTAIN KEY HOLDERS March 10, 2014 (Filed With SEC on May 11, 2016)

ONCOBIOLOGICS, INC. Formof Warrant to Purchase Common Stock (Filed With SEC on May 11, 2016)

Oncobiologics, Inc. [________] Shares1 Common Stock ($0.01 par value) Underwriting Agreement (Filed With SEC on April 27, 2016)

INVESTORS’ RIGHTS AGREEMENT by and among ONCOBIOLOGICS, INC., STRIDES PHARMA INC. and CERTAIN KEY HOLDERS March 10, 2014 (Filed With SEC on April 27, 2016)

EXECUTIVEEmployment Agreement (Filed With SEC on April 27, 2016)

Amended and Restated Performance StockUnit Agreement (Filed With SEC on April 27, 2016)

ONCOBIOLOGICS, INC. Formof Warrant to Purchase Common Stock (Filed With SEC on April 27, 2016)

CONFIDENTIAL (Filed With SEC on February 26, 2016)

Oncobiologics,Inc. 2016 Employee Stock Purchase Plan Adoptedby the Board of Directors: January 28, 2016 Approvedby the Stockholders: January 28, 2016 (Filed With SEC on February 12, 2016)

INVESTORS’ RIGHTS AGREEMENT by and among ONCOBIOLOGICS, INC., STRIDES PHARMA INC. and CERTAIN KEY HOLDERS March 10, 2014 (Filed With SEC on January 15, 2016)

Oncobiologics Inc STOCK INCENTIVE PLAN ArticleI ESTABLISHMENT AND PURPOSES (Filed With SEC on January 15, 2016)

Oncobiologics,Inc. 2015Equity Incentive Plan Adoptedby the Board of Directors: December 4, 2015 Approvedby the Stockholders: December 7, 2015 EffectiveDate: December 4, 2015 (Filed With SEC on January 15, 2016)

Oncobiologics,Inc. 2015 Equity Incentive Plan StockOption Grant Notice (Filed With SEC on January 15, 2016)

EMPLOYMENTAGREEMENT (Filed With SEC on January 15, 2016)

Pankaj Mohan PhD MBA Founder & CEO 7 Clarke Drive, Cranbury New Jersey 08512 (Filed With SEC on January 15, 2016)

IndemnityAgreement (Filed With SEC on January 15, 2016)

CONFIDENTIAL (Filed With SEC on January 15, 2016)

AND Oncobiologics, Inc. Commercial License Agreement April 11, 2013 (Filed With SEC on January 15, 2016)

JointParticipation Agreement ByAnd Between Oncobiologics,Inc. And ZhejiangHuahai Pharmaceutical Co., Ltd. Effectiveas of May 6 , 2013 (Filed With SEC on January 15, 2016)

L E A S E A G R E E M E N T (Filed With SEC on January 15, 2016)

FIRSTAMENDMENT TO LEASE (Filed With SEC on January 15, 2016)

SECONDAMENDMENT TO LEASE (Filed With SEC on January 15, 2016)

THIRDAMENDMENT TO LEASE (Filed With SEC on January 15, 2016)

FOURTHAMENDMENT TO LEASE (Filed With SEC on January 15, 2016)

fifthAMENDMENT TO LEASE (Filed With SEC on January 15, 2016)

L E AS E A G R E E M E N T (Filed With SEC on January 15, 2016)

Category

Industry

Companies

Contracts

Outlook Therapeutics, Inc. Contracts & Agreements